Dr Reddy S
Latest news, explainers and analysis on Dr Reddy S. Tracking 3 stories on Arth Vani.
Connected in the graph
Latest on Dr Reddy S
Dr. Reddy's Semaglutide Supply Faces Delay, No Recall Risk
Dr. Reddy's Laboratories has announced a delay in the supply of its Semaglutide, a key diabetes and weight-loss drug. The company clarified that this is a supply chain issue and not related to any quality concerns or a product recall.
Nifty Reclaims 23,500: Key Stocks to Watch as Market Sentiment Recovers
The Indian stock market showed strong signs of recovery on Friday as the Nifty 50 climbed back above the critical 23,500 level. Retail investors should keep a close eye on major players like Dr. Reddy’s and Adani Green following significant corporate developments.
Dr Reddy’s Shares Slip Below Key Levels; Analysts Signal Bearish Trend
Shares of pharmaceutical giant Dr Reddy's Laboratories have fallen below their 100-day moving average, a key technical indicator used by traders to gauge long-term momentum. This breach suggests a potential downward trend for the Nifty 50 constituent, which is a staple in many Indian retail and mutual fund portfolios.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.